Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 73
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Eur J Neurol ; 29(4): 1187-1197, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-34967067

RESUMO

BACKGROUND AND PURPOSE: Anti-acetylcholine receptor (AChR) antibodies (ab) in the serum are detected in most patients with generalized myasthenia gravis (MG) and used as a diagnostic tool. The aim of this study was to analyse a possible association between anti-AChR-ab serum levels and clinical improvement of MG. METHODS: The Maastricht University Medical Center is a centre of expertise for the treatment of MG. Between 1997 and 2020, more than 4000 anti-AChR-ab blood samples were measured for clinical care using a quantitative radioimmunoassay technique. These results, in combination with clinical status obtained from the patients' electronic patient files, were retrospectively analysed by a single blinded clinician. Symptoms of MG were classified using the Myasthenia Gravis Foundation of America (MGFA) scale. RESULTS: In total, 90 anti-AChR-ab-positive MG patients with 837 blood samples were included. The median follow-up time was 72 months. The majority of the included patients were women (61.1%), were on immunosuppressive drug therapy (88.9%), and underwent a thymectomy (54.4%). Multilevel logistic regression analysis showed a significantly inverse association between change in anti-AChR-ab level and the odds of MGFA improvement (per 10% decrease of anti-AChR-ab level: odds ratio 1.21, 95% confidence interval 1.12-1.31; p < 0.001). CONCLUSIONS: A change in anti-AChR-ab serum level is associated with clinical status in patients with MG. Analyses of anti-AChR-ab are not only useful for diagnostics but also in follow-up of adult symptomatic patients with MG. The use of repetitive anti-AChR-ab serum levels might be valuable in long-term monitoring for clinical improvement in patients with MG, however, further research is required for specific recommendations.


Assuntos
Miastenia Gravis , Receptores Colinérgicos , Adulto , Autoanticorpos , Feminino , Humanos , Masculino , Estudos Retrospectivos , Timectomia
2.
Am J Pathol ; 186(10): 2559-68, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27658713

RESUMO

Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies that target proteins at the neuromuscular junction, primarily the acetylcholine receptor (AChR) and the muscle-specific kinase. Because downstream of kinase 7 (Dok-7) is essential for the full activation of muscle-specific kinase and consequently for dense clustering of AChRs, we hypothesized that reduced levels of Dok-7 increase the susceptibility to passive transfer MG. To test this hypothesis, Dok-7 expression was reduced by transfecting shRNA-coding plasmids into the tibialis anterior muscle of adult rats by in vivo electroporation. Subclinical MG was subsequently induced with a low dose of anti-AChR monoclonal antibody 35. Neuromuscular transmission was significantly impaired in Dok-7-siRNA-electroporated legs compared with the contralateral control legs, which correlated with a reduction of AChR protein levels at the neuromuscular junction (approximately 25%) in Dok-7-siRNA-electroporated muscles, compared with contralateral control muscles. These results suggest that a reduced expression of Dok-7 may play a role in the susceptibility to passive transfer MG, by rendering AChR clusters less resistant to the autoantibody attack.


Assuntos
Autoanticorpos/imunologia , Proteínas Musculares/genética , Miastenia Gravis Autoimune Experimental/genética , Animais , Modelos Animais de Doenças , Suscetibilidade a Doenças , Regulação para Baixo , Feminino , Inativação Gênica , Genes Reporter , Células HEK293 , Humanos , Proteínas Musculares/metabolismo , Músculo Esquelético/imunologia , Músculo Esquelético/fisiopatologia , Miastenia Gravis Autoimune Experimental/imunologia , Miastenia Gravis Autoimune Experimental/fisiopatologia , Junção Neuromuscular/imunologia , Junção Neuromuscular/fisiopatologia , Ratos , Ratos Endogâmicos Lew , Receptores Proteína Tirosina Quinases/genética , Receptores Proteína Tirosina Quinases/metabolismo , Receptores Colinérgicos/genética , Receptores Colinérgicos/metabolismo , Transmissão Sináptica
3.
J Autoimmun ; 82: 62-73, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28549776

RESUMO

OBJECTIVE: To identify novel genetic and epigenetic factors associated with Myasthenia gravis (MG) using an identical twins experimental study design. METHODS: The transcriptome and methylome of peripheral monocytes were compared between monozygotic (MZ) twins discordant and concordant for MG, as well as with MG singletons and healthy controls, all females. Sets of differentially expressed genes and differentially methylated CpGs were validated using RT-PCR for expression and target bisulfite sequencing for methylation on additional samples. RESULTS: >100 differentially expressed genes and ∼1800 differentially methylated CpGs were detected in peripheral monocytes between MG patients and controls. Several transcripts associated with immune homeostasis and inflammation resolution were reduced in MG patients. Only a relatively few genes differed between the discordant healthy and MG co-twins, and both their expression and methylation profiles demonstrated very high similarity. INTERPRETATION: This is the first study to characterize the DNA methylation profile in MG, and the expression profile of immune cells in MZ twins with MG. Results suggest that numerous small changes in gene expression or methylation might together contribute to disease. Impaired monocyte function in MG and decreased expression of genes associated with inflammation resolution could contribute to the chronicity of the disease. Findings may serve as potential new predictive biomarkers for disease and disease activity, as well as potential future targets for therapy development. The high similarity between the healthy and the MG discordant twins, suggests that a molecular signature might precede a clinical phenotype, and that genetic predisposition may have a stronger contribution to disease than previously assumed.


Assuntos
Metilação de DNA , Miastenia Gravis/genética , Transcriptoma , Gêmeos Monozigóticos , Adulto , Idoso , Estudos de Casos e Controles , Ilhas de CpG , Epigênese Genética , Feminino , Perfilação da Expressão Gênica , Estudos de Associação Genética , Predisposição Genética para Doença , Humanos , Pessoa de Meia-Idade , Monócitos/imunologia , Monócitos/metabolismo , Miastenia Gravis/metabolismo , Transdução de Sinais , Receptor Gatilho 1 Expresso em Células Mieloides/genética , Receptor Gatilho 1 Expresso em Células Mieloides/metabolismo , Adulto Jovem
4.
J Autoimmun ; 77: 104-115, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27965060

RESUMO

Autoimmunity mediated by IgG4 subclass autoantibodies is an expanding field of research. Due to their structural characteristics a key feature of IgG4 antibodies is the ability to exchange Fab-arms with other, unrelated, IgG4 molecules, making the IgG4 molecule potentially monovalent for the specific antigen. However, whether those disease-associated antigen-specific IgG4 are mono- or divalent for their antigens is unknown. Myasthenia gravis (MG) with antibodies to muscle specific kinase (MuSK-MG) is a well-recognized disease in which the predominant pathogenic IgG4 antibody binds to extracellular epitopes on MuSK at the neuromuscular junction; this inhibits a pathway that clusters the acetylcholine (neurotransmitter) receptors and leads to failure of neuromuscular transmission. In vitro Fab-arm exchange-inducing conditions were applied to MuSK antibodies in sera, purified IgG4 and IgG1-3 sub-fractions. Solid-phase cross-linking assays were established to determine the extent of pre-existing and inducible Fab-arm exchange. Functional effects of the resulting populations of IgG4 antibodies were determined by measuring inhibition of agrin-induced AChR clustering in C2C12 cells. To confirm the results, κ/κ, λ/λ and hybrid κ/λ IgG4s were isolated and tested for MuSK antibodies. At least fifty percent of patients had IgG4, but not IgG1-3, MuSK antibodies that could undergo Fab-arm exchange in vitro under reducing conditions. Also MuSK antibodies were found in vivo that were divalent (monospecific for MuSK). Fab-arm exchange with normal human IgG4 did not prevent the inhibitory effect of serum derived MuSK antibodies on AChR clustering in C2C12 mouse myotubes. The results suggest that a considerable proportion of MuSK IgG4 could already be Fab-arm exchanged in vivo. This was confirmed by isolating endogenous IgG4 MuSK antibodies containing both κ and λ light chains, i.e. hybrid IgG4 molecules. These new findings demonstrate that Fab-arm exchanged antibodies are pathogenic.


Assuntos
Autoanticorpos/imunologia , Autoantígenos/imunologia , Fragmentos Fab das Imunoglobulinas/imunologia , Imunoglobulina G/imunologia , Miastenia Gravis/imunologia , Receptores Proteína Tirosina Quinases/imunologia , Receptores Colinérgicos/imunologia , Adolescente , Adulto , Idoso , Anticorpos Biespecíficos/imunologia , Afinidade de Anticorpos/imunologia , Autoanticorpos/sangue , Autoimunidade/imunologia , Feminino , Humanos , Imunoglobulina G/sangue , Masculino , Pessoa de Meia-Idade , Miastenia Gravis/diagnóstico , Adulto Jovem
5.
J Immunol ; 192(3): 1154-61, 2014 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-24395916

RESUMO

C1q is the initiator of the classical complement pathway and, as such, is essential for efficient opsonization and clearance of pathogens, altered self-structures, and apoptotic cells. The ceramide transporter protein (CERT) and its longer splicing isoform CERTL are known to interact with extracellular matrix components, such as type IV collagen, and with the innate immune protein serum amyloid P. In this article, we report a novel function of CERT in the innate immune response. Both CERT isoforms, when immobilized, were found to bind the globular head region of C1q and to initiate the classical complement pathway, leading to activation of C4 and C3, as well as generation of the membrane attack complex C5b-9. In addition, C1q was shown to bind to endogenous CERTL on the surface of apoptotic cells. These results demonstrate the role of CERTs in innate immunity, especially in the clearance of apoptotic cells.


Assuntos
Complemento C1q/metabolismo , Via Clássica do Complemento , Proteínas Serina-Treonina Quinases/fisiologia , Anticorpos Monoclonais/imunologia , Apoptose/imunologia , Sítios de Ligação , Complemento C1q/imunologia , Via Alternativa do Complemento/efeitos dos fármacos , Via Clássica do Complemento/efeitos dos fármacos , Humanos , Imunidade Inata , Células Jurkat , Ligação Proteica , Mapeamento de Interação de Proteínas , Isoformas de Proteínas/metabolismo , Proteínas Serina-Treonina Quinases/genética , Proteínas Serina-Treonina Quinases/isolamento & purificação , Proteínas Serina-Treonina Quinases/farmacologia , Estrutura Terciária de Proteína , Proteínas Recombinantes de Fusão/farmacologia , Componente Amiloide P Sérico/fisiologia
6.
J Immunol ; 193(3): 1055-1063, 2014 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-24973445

RESUMO

Bortezomib is a potent inhibitor of proteasomes currently used to eliminate malignant plasma cells in multiple myeloma patients. It is also effective in depleting both alloreactive plasma cells in acute Ab-mediated transplant rejection and their autoreactive counterparts in animal models of lupus and myasthenia gravis (MG). In this study, we demonstrate that bortezomib at 10 nM or higher concentrations killed long-lived plasma cells in cultured thymus cells from nine early-onset MG patients and consistently halted their spontaneous production not only of autoantibodies against the acetylcholine receptor but also of total IgG. Surprisingly, lenalidomide and dexamethasone had little effect on plasma cells. After bortezomib treatment, they showed ultrastructural changes characteristic of endoplasmic reticulum stress after 8 h and were no longer detectable at 24 h. Bortezomib therefore appears promising for treating MG and possibly other Ab-mediated autoimmune or allergic disorders, especially when given in short courses at modest doses before the standard immunosuppressive drugs have taken effect.


Assuntos
Autoanticorpos/metabolismo , Ácidos Borônicos/farmacologia , Plasmócitos/imunologia , Complexo de Endopeptidases do Proteassoma/imunologia , Complexo de Endopeptidases do Proteassoma/metabolismo , Pirazinas/farmacologia , Timo/imunologia , Adolescente , Adulto , Idade de Início , Antineoplásicos/farmacologia , Autoanticorpos/biossíntese , Autoanticorpos/efeitos dos fármacos , Bortezomib , Células Cultivadas , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Estresse do Retículo Endoplasmático/imunologia , Feminino , Humanos , Masculino , Plasmócitos/efeitos dos fármacos , Plasmócitos/ultraestrutura , Cultura Primária de Células , Complexo de Endopeptidases do Proteassoma/efeitos dos fármacos , Timo/efeitos dos fármacos , Timo/ultraestrutura , Adulto Jovem
7.
Curr Opin Neurol ; 27(5): 552-7, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25105461

RESUMO

PURPOSE OF REVIEW: Myasthenia gravis is a rare disease that causes impairment of the neuromuscular junction. In this review we will focus on the literature published in the last 18 months regarding autoimmune myasthenia gravis caused by antibodies against the nicotinic acetylcholine receptor myasthenia gravis. Acetylcholine receptor is the most common target of this autoimmune disease. RECENT FINDINGS: A high number of long-lived plasma cells are present in myasthenia gravis patients. Treatments to eliminate these plasma cells, such as proteasome inhibitors, have proved utility in experimental autoimmune myasthenia gravis. MicroRNAs may have a role as biomarkers in myasthenia gravis. Epstein-Barr virus and human polyomavirus 7 are often found in myasthenia gravis thymus and may play a role in the initiation of the autoimmune process. Robotic thymectomy has been proved well tolerated and minimally invasive for the patients and is likely to replace open surgery. SUMMARY: Knowledge of the initiation and perpetuation of the autoimmune response in myasthenia gravis condition is increasing every year. This knowledge is paired with in-vivo and in-vitro studies that are directed to further understand this disease, and to improve current treatment options in severe or nonresponding patients. Specific treatments and diagnosis in myasthenia gravis tend to an early detection and a better quality of life.


Assuntos
Autoanticorpos/sangue , Miastenia Gravis , Receptores Colinérgicos/imunologia , Autoimunidade , Bases de Dados Bibliográficas/estatística & dados numéricos , Herpesvirus Humano 4 , Humanos , MicroRNAs/genética , MicroRNAs/metabolismo , Miastenia Gravis/genética , Miastenia Gravis/patologia , Miastenia Gravis/terapia , Polyomavirus , Timectomia
8.
J Autoimmun ; 52: 101-12, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24439114

RESUMO

Myasthenia gravis (MG) with antibodies against the acetylcholine receptor (AChR-MG) is considered as a prototypic autoimmune disease. The thymus is important in the pathophysiology of the disease since thymus hyperplasia is a characteristic of early-onset AChR-MG and patients often improve after thymectomy. We hypothesized that thymic B cell and antibody repertoires of AChR-MG patients differ intrinsically from those of control individuals. Using immortalization with Epstein-Barr Virus and Toll-like receptor 9 activation, we isolated and characterized monoclonal B cell lines from 5 MG patients and 8 controls. Only 2 of 570 immortalized B cell clones from MG patients produced antibodies against the AChR (both clones were from the same patient), suggesting that AChR-specific B cells are not enriched in the thymus. Surprisingly, many B cell lines from both AChR-MG and control thymus samples displayed reactivity against striated muscle proteins. Striational antibodies were produced by 15% of B cell clones from AChR-MG versus 6% in control thymus. The IgVH gene sequence analysis showed remarkable similarities, concerning VH family gene distribution, mutation frequency and CDR3 composition, between B cells of AChR-MG patients and controls. MG patients showed clear evidence of clonal B cell expansion in contrast to controls. In this latter aspect, MG resembles multiple sclerosis and clinically isolated syndrome, but differs from systemic lupus erythematosus. Our results support an antigen driven immune response in the MG thymus, but the paucity of AChR-specific B cells, in combination with the observed polyclonal expansions suggest a more diverse immune response than expected.


Assuntos
Autoanticorpos/imunologia , Linfócitos B/imunologia , Herpesvirus Humano 4/fisiologia , Miastenia Gravis/imunologia , Timo/patologia , Adulto , Autoanticorpos/sangue , Linhagem Celular Transformada , Transformação Celular Viral , Células Clonais , Feminino , Humanos , Hiperplasia , Músculo Estriado/imunologia , Mutação/genética , Receptores Colinérgicos/imunologia , Anticorpos de Domínio Único/genética , Receptor Toll-Like 9/metabolismo , Adulto Jovem
9.
Ann Neurol ; 73(2): 281-93, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23280437

RESUMO

OBJECTIVE: Myasthenia gravis (MG) is an autoimmune disease mediated mainly by anti-acetylcholine receptor (AChR) antibodies. The thymus plays a primary role in MG pathogenesis. As we recently showed an inflammatory and antiviral signature in MG thymuses, we investigated whether pathogen-sensing molecules could contribute to an anti-AChR response. METHODS: We studied the effects of toll-like receptor agonists on the expression of α-AChR and various tissue-specific antigens (TSAs) in human thymic epithelial cell (TEC) cultures. As polyinosinic-polycytidylic acid (poly[I:C]), which mimics double-stranded RNA (dsRNA), stimulated specifically α-AChR expression, the signaling pathways involved were investigated. In parallel, we analyzed the expression of dsRNA-signaling components in the thymus of MG patients, and the relevance of our data was investigated in vivo in poly(I:C)-injected mice. RESULTS: We demonstrate that dsRNA signaling induced by poly(I:C) specifically triggers the overexpression of α-AChR in TECs and not of other TSAs. A poly(I:C) effect was also observed on MG TECs. This induction is mediated through toll-like receptor 3 (TLR3) and protein kinase R (PKR), and by the release of interferon (IFN)-ß. In parallel, human MG thymuses also display an overexpression of TLR3, PKR, and IFN-ß. In addition, poly(I:C) injections specifically increase thymic expression of α-AChR in wild-type mice, but not in IFN-I receptor knockout mice. These injections also lead to an anti-AChR autoimmune response characterized by a significant production of serum anti-AChR antibodies and a specific proliferation of B cells. INTERPRETATION: Because anti-AChR antibodies are highly specific for MG and are pathogenic, dsRNA-signaling activation could contribute to the etiology of MG.


Assuntos
Miastenia Gravis/genética , Miastenia Gravis/imunologia , Poli I-C/imunologia , RNA de Cadeia Dupla/imunologia , Transdução de Sinais/genética , Adolescente , Adulto , Animais , Especificidade de Anticorpos , Autoanticorpos/sangue , Autoanticorpos/imunologia , Autoimunidade/genética , Autoimunidade/imunologia , Linfócitos B/imunologia , Células Cultivadas , Expressão Gênica/efeitos dos fármacos , Expressão Gênica/imunologia , Humanos , Lactente , Indutores de Interferon/imunologia , Indutores de Interferon/metabolismo , Indutores de Interferon/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Miastenia Gravis/etiologia , Poli I-C/metabolismo , Poli I-C/farmacologia , RNA de Cadeia Dupla/metabolismo , RNA de Cadeia Dupla/farmacologia , RNA Mensageiro/genética , Receptores Colinérgicos/genética , Receptores Colinérgicos/imunologia , Transdução de Sinais/imunologia , Timo/citologia , Adulto Jovem
10.
Front Immunol ; 15: 1325171, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38715598

RESUMO

Introduction: Muscle-specific kinase (MuSK)- myasthenia gravis (MG) is caused by pathogenic autoantibodies against MuSK that correlate with disease severity and are predominantly of the IgG4 subclass. The first-line treatment for MuSK-MG is general immunosuppression with corticosteroids, but the effect of treatment on IgG4 and MuSK IgG4 levels has not been studied. Methods: We analyzed the clinical data and sera from 52 MuSK-MG patients (45 female, 7 male, median age 49 (range 17-79) years) from Italy, the Netherlands, Greece and Belgium, and 43 AChR-MG patients (22 female, 21 male, median age 63 (range 2-82) years) from Italy, receiving different types of immunosuppression, and sera from 46 age- and sex-matched non-disease controls (with no diagnosed diseases, 38 female, 8 male, median age 51.5 (range 20-68) years) from the Netherlands. We analyzed the disease severity (assessed by MGFA or QMG score), and measured concentrations of MuSK IgG4, MuSK IgG, total IgG4 and total IgG in the sera by ELISA, RIA and nephelometry. Results: We observed that MuSK-MG patients showed a robust clinical improvement and reduction of MuSK IgG after therapy, and that MuSK IgG4 concentrations, but not total IgG4 concentrations, correlated with clinical severity. MuSK IgG and MuSK IgG4 concentrations were reduced after immunosuppression in 4/5 individuals with before-after data, but data from non-linked patient samples showed no difference. Total serum IgG4 levels were within the normal range, with IgG4 levels above threshold (1.35g/L) in 1/52 MuSK-MG, 2/43 AChR-MG patients and 1/45 non-disease controls. MuSK-MG patients improved within the first four years after disease onset, but no further clinical improvement or reduction of MuSK IgG4 were observed four years later, and only 14/52 (26.92%) patients in total, of which 13 (93.3%) received general immunosuppression, reached clinical remission. Discussion: We conclude that MuSK-MG patients improve clinically with general immunosuppression but may require further treatment to reach remission. Longitudinal testing of individual patients may be clinically more useful than single measurements of MuSK IgG4. No significant differences in the serum IgG4 concentrations and IgG4/IgG ratio between AChR- and MuSK-MG patients were found during follow-up. Further studies with larger patient and control cohorts are necessary to validate the findings.


Assuntos
Autoanticorpos , Imunoglobulina G , Miastenia Gravis , Receptores Proteína Tirosina Quinases , Receptores Colinérgicos , Humanos , Miastenia Gravis/imunologia , Miastenia Gravis/sangue , Miastenia Gravis/diagnóstico , Masculino , Pessoa de Meia-Idade , Feminino , Adulto , Idoso , Receptores Proteína Tirosina Quinases/imunologia , Receptores Colinérgicos/imunologia , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Estudos Retrospectivos , Adulto Jovem , Adolescente , Autoanticorpos/sangue , Autoanticorpos/imunologia , Idoso de 80 Anos ou mais , Terapia de Imunossupressão , Imunossupressores/uso terapêutico , Índice de Gravidade de Doença , Criança
11.
J Lipid Res ; 54(7): 1825-33, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23625371

RESUMO

Fetal asphyctic preconditioning, induced by a brief episode of experimental hypoxia-ischemia, offers neuroprotection to a subsequent more severe asphyctic insult at birth. Extensive cell stress and apoptosis are important contributing factors of damage in the asphyctic neonatal brain. Because ceramide acts as a second messenger for multiple apoptotic stimuli, including hypoxia/ischemia, we sought to investigate the possible involvement of the ceramide pathway in endogenous neuroprotection induced by fetal asphyctic preconditioning. Global fetal asphyxia was induced in rats by clamping both uterine and ovarian vasculature for 30 min. Fetal asphyxia resulted in acute changes in brain ceramide/sphingomyelin metabolic enzymes, ceramide synthase 1, 2, and 5, acid sphingomyelinase, sphingosine-1-phosphate phosphatase, and the ceramide transporter. This observation correlated with an increase in neuronal apoptosis and in astrocyte number. After birth, ceramide and sphingomyelin levels remained high in fetal asphyxia brains, suggesting that a long-term regulation of the ceramide pathway may be involved in the mechanism of tolerance to a subsequent, otherwise lethal, asphyctic event.


Assuntos
Asfixia/metabolismo , Encéfalo/metabolismo , Ceramidas/metabolismo , Hipóxia Fetal/metabolismo , Prenhez , Animais , Encéfalo/patologia , Feminino , Gravidez , Ratos , Ratos Sprague-Dawley , Esfingomielinas/metabolismo
12.
J Biol Chem ; 287(18): 14897-911, 2012 Apr 27.
Artigo em Inglês | MEDLINE | ID: mdl-22396542

RESUMO

Serum amyloid P component (SAP) is a non-fibrillar glycoprotein belonging to the pentraxin family of the innate immune system. SAP is present in plasma, basement membranes, and amyloid deposits. This study demonstrates, for the first time, that the Goodpasture antigen-binding protein (GPBP) binds to human SAP. GPBP is a nonconventional Ser/Thr kinase for basement membrane type IV collagen. Also GPBP is found in plasma and in the extracellular matrix. In the present study, we demonstrate that GPBP specifically binds SAP in its physiological conformations, pentamers and decamers. The START domain in GPBP is important for this interaction. SAP and GPBP form complexes in blood and partly colocalize in amyloid plaques from Alzheimer disease patients. These data suggest the existence of complexes of SAP and GPBP under physiological and pathological conditions. These complexes are important for understanding basement membrane, blood physiology, and plaque formation in Alzheimer disease.


Assuntos
Doença de Alzheimer/sangue , Encéfalo/metabolismo , Complexos Multiproteicos/sangue , Proteínas Serina-Treonina Quinases/sangue , Componente Amiloide P Sérico/metabolismo , Doença de Alzheimer/genética , Animais , Humanos , Camundongos , Camundongos Transgênicos , Complexos Multiproteicos/genética , Ligação Proteica , Proteínas Serina-Treonina Quinases/genética , Estrutura Terciária de Proteína , Componente Amiloide P Sérico/genética
13.
J Immunol ; 186(4): 2503-13, 2011 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-21239719

RESUMO

Bortezomib, an inhibitor of proteasomes, has been reported to reduce autoantibody titers and to improve clinical condition in mice suffering from lupus-like disease. Bortezomib depletes both short- and long-lived plasma cells; the latter normally survive the standard immunosuppressant treatments targeting T and B cells. These findings encouraged us to test whether bortezomib is effective for alleviating the symptoms in the experimental autoimmune myasthenia gravis (EAMG) model for myasthenia gravis, a disease that is characterized by autoantibodies against the acetylcholine receptor (AChR) of skeletal muscle. Lewis rats were immunized with saline (control, n = 36) or Torpedo AChR (EAMG, n = 54) in CFA in the first week of an experimental period of 8 wk. After immunization, rats received twice a week s.c. injections of bortezomib (0.2 mg/kg in saline) or saline injections. Bortezomib induced apoptosis in bone marrow cells and reduced the amount of plasma cells in the bone marrow by up to 81%. In the EAMG animals, bortezomib efficiently reduced the rise of anti-AChR autoantibody titers, prevented ultrastructural damage of the postsynaptic membrane, improved neuromuscular transmission, and decreased myasthenic symptoms. This study thus underscores the potential of the therapeutic use of proteasome inhibitors to target plasma cells in Ab-mediated autoimmune diseases.


Assuntos
Autoanticorpos/efeitos dos fármacos , Ácidos Borônicos/farmacologia , Miastenia Gravis Autoimune Experimental/tratamento farmacológico , Miastenia Gravis Autoimune Experimental/imunologia , Plasmócitos/efeitos dos fármacos , Inibidores de Proteases/farmacologia , Inibidores de Proteassoma , Pirazinas/farmacologia , Animais , Autoanticorpos/biossíntese , Bortezomib , Feminino , Depleção Linfocítica/métodos , Miastenia Gravis Autoimune Experimental/enzimologia , Plasmócitos/enzimologia , Plasmócitos/patologia , Ratos , Ratos Endogâmicos Lew
14.
Brain ; 135(Pt 4): 1081-101, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22396395

RESUMO

Myasthenia gravis is a paralytic disorder with autoantibodies against acetylcholine receptors at the neuromuscular junction. A proportion of patients instead has antibodies against muscle-specific kinase, a protein essential for acetylcholine receptor clustering. These are generally of the immunoglobulin-G4 subclass and correlate with disease severity, suggesting specific myasthenogenic activity. However, immunoglobulin-G4 subclass antibodies are generally considered to be 'benign' and direct proof for their pathogenicity in muscle-specific kinase myasthenia gravis (or other immunoglobulin-G4-associated disorders) is lacking. Furthermore, the exact electrophysiological synaptic defects caused at neuromuscular junctions by human anti-muscle-specific kinase autoantibodies are hitherto unknown. We show that purified immunoglobulin-G4, but not immunoglobulin-G1-3, from patients with muscle-specific kinase myasthenia gravis binds to mouse neuromuscular junctions in vitro, and that injection into immunodeficient mice causes paralysis. Injected immunoglobulin-G4 caused reduced density and fragmented area of neuromuscular junction acetylcholine receptors. Detailed electrophysiological synaptic analyses revealed severe reduction of postsynaptic acetylcholine sensitivity, and exaggerated depression of presynaptic acetylcholine release during high-rate activity, together causing the (fatigable) muscle weakness. Intriguingly, compensatory transmitter release upregulation, which is the normal homeostatic response in acetylcholine receptor myasthenia gravis, was absent. This conveys extra vulnerability to neurotransmission at muscle-specific kinase myasthenia gravis neuromuscular junctions. Thus, we demonstrate that patient anti-muscle-specific kinase immunoglobulin-G4 is myasthenogenic, independent of additional immune system components, and have elucidated the underlying electrophysiological neuromuscular junction abnormalities.


Assuntos
Imunoglobulina G/efeitos adversos , Imunoglobulina G/sangue , Miastenia Gravis/sangue , Doenças da Junção Neuromuscular/complicações , Receptores Proteína Tirosina Quinases/imunologia , Receptores Colinérgicos/imunologia , Potenciais de Ação/efeitos dos fármacos , Adulto , Animais , Autoanticorpos/sangue , Modelos Animais de Doenças , Eletromiografia , Feminino , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos SCID , Microscopia Eletrônica de Transmissão , Pessoa de Meia-Idade , Placa Motora/efeitos dos fármacos , Placa Motora/fisiopatologia , Contração Muscular/efeitos dos fármacos , Força Muscular/efeitos dos fármacos , Força Muscular/fisiologia , Miastenia Gravis/complicações , Miastenia Gravis/imunologia , Miastenia Gravis/terapia , Condução Nervosa/efeitos dos fármacos , Condução Nervosa/fisiologia , Junção Neuromuscular/efeitos dos fármacos , Junção Neuromuscular/patologia , Junção Neuromuscular/fisiopatologia , Junção Neuromuscular/ultraestrutura , Doenças da Junção Neuromuscular/patologia , Plasmaferese/métodos , Adulto Jovem
15.
Neuromuscul Disord ; 33(5): 417-424, 2023 05.
Artigo em Inglês | MEDLINE | ID: mdl-37037051

RESUMO

The aim of this study was to investigate the surgical and long-term neurological outcomes of patients with acetylcholine-receptor-antibody-associated myasthenia gravis (AChR-MG) who underwent robotic thymectomy (RATS). We retrospectively analyzed the clinical-pathological data of all patients with AChR-MG who underwent RATS using the DaVinci® Robotic System at the MUMC+ between April 2004 and December 2018. Follow-up data were collected from 60 referring Dutch hospitals. In total, 230 myasthenic patients including 76 patients with a thymoma (33.0%) were enrolled in this study. Mean follow-up time, procedure time and hospitalization were, respectively 65.7 ± 43.1 months, 111±52.5 min and 3.3 ± 2.2 days. Thymomatous patients had significantly more frequently and more severe complications than nonthymomatous patients (18.4% vs. 3.9%, p<0.001). Follow up data was available in 71.7% of the included patients. The Myasthenia Gravis Foundation of America postintervention score showed any kind of improvement of MG-symptoms after RATS in 82.4% of the patients. Complete stable remission (CSR) or pharmacological remission (PR) of MG was observed in 8.4% and 39.4% of the patients, respectively. Mean time till CSR/PR remission after thymectomy was 26.2 ± 29.2 months. No statistical difference was found in remission or improvement in MGFA scale between thymomatous and nonthymomatous patients. RATS is safe and feasible in patients with MG. The majority of the patients (82.4%) improved after thymectomy. CSR and PR were observed in 8.4% and 39.4% of the patients, respectively, with a mean of 26.2 months after thymectomy. Thymomatous patients had more frequently and more severe complications compared to nonthymomatous patients.


Assuntos
Miastenia Gravis , Procedimentos Cirúrgicos Robóticos , Neoplasias do Timo , Humanos , Timectomia , Acetilcolina , Resultado do Tratamento , Procedimentos Cirúrgicos Robóticos/efeitos adversos , Estudos Retrospectivos , Miastenia Gravis/cirurgia , Miastenia Gravis/complicações , Neoplasias do Timo/complicações , Receptores Colinérgicos , Autoanticorpos
16.
Histochem Cell Biol ; 137(2): 205-16, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22127648

RESUMO

Perilipin 5 (PLIN5/OXPAT) is a lipid droplet (LD) coat protein mainly present in tissues with a high fat-oxidative capacity, suggesting a role for PLIN5 in facilitating fatty acid oxidation. Here, we investigated the role of PLIN5 in fat oxidation in skeletal muscle. In human skeletal muscle, we observed that PLIN5 (but not PLIN2) protein content correlated tightly with OXPHOS content and in rat muscle PLIN5 content correlated with mitochondrial respiration rates on a lipid-derived substrate. This prompted us to examine PLIN5 protein expression in skeletal muscle mitochondria by means of immunogold electron microscopy and Western blots in isolated mitochondria. These data show that PLIN5, in contrast to PLIN2, not only localizes to LD but also to mitochondria, possibly facilitating fatty acid oxidation. Unilateral overexpression of PLIN5 in rat anterior tibialis muscle augmented myocellular fat storage without increasing mitochondrial density as indicated by the lack of change in protein content of five components of the OXPHOS system. Mitochondria isolated from PLIN5 overexpressing muscles did not possess increased fatty acid respiration. Interestingly though, (14)C-palmitate oxidation assays in muscle homogenates from PLIN5 overexpressing muscles revealed a 44.8% (P = 0.05) increase in complete fatty acid oxidation. Thus, in mitochondrial isolations devoid of LD, PLIN5 does not augment fat oxidation, while in homogenates containing PLIN5-coated LD, fat oxidation is higher upon PLIN5 overexpression. The presence of PLIN5 in mitochondria helps to understand why PLIN5, in contrast to PLIN2, is of specific importance in fat oxidative tissues. Our data suggests involvement of PLIN5 in directing fatty acids from the LD to mitochondrial fatty acid oxidation.


Assuntos
Ácidos Graxos/metabolismo , Mitocôndrias Musculares/metabolismo , Músculo Esquelético/metabolismo , Proteínas/metabolismo , Adulto , Animais , Proteínas de Transporte/metabolismo , Técnicas de Cultura de Células , Células HEK293 , Humanos , Metabolismo dos Lipídeos , Masculino , Oxirredução , Perilipina-1 , Perilipina-5 , Fosfoproteínas/metabolismo , Ratos
17.
Autoimmun Rev ; 21(7): 103104, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-35452851

RESUMO

The presence of autoantibodies directed against the muscle nicotinic acetylcholine receptor (AChR) is the most common cause of myasthenia gravis (MG). These antibodies damage the postsynaptic membrane of the neuromuscular junction and cause muscle weakness by depleting AChRs and thus impairing synaptic transmission. As one of the best-characterized antibody-mediated autoimmune diseases, AChR-MG has often served as a reference model for other autoimmune disorders. Classical pharmacological treatments, including broad-spectrum immunosuppressive drugs, are effective in many patients. However, complete remission cannot be achieved in all patients, and 10% of patients do not respond to currently used therapies. This may be attributed to production of autoantibodies by long-lived plasma cells which are resistant to conventional immunosuppressive drugs. Hence, novel therapies specifically targeting plasma cells might be a suitable therapeutic approach for selected patients. Additionally, in order to reduce side effects of broad-spectrum immunosuppression, targeted immunotherapies and symptomatic treatments will be required. This review presents established therapies as well as novel therapeutic approaches for MG and related conditions, with a focus on AChR-MG.


Assuntos
Miastenia Gravis , Receptores Colinérgicos , Autoanticorpos , Humanos , Terapia de Imunossupressão , Imunossupressores/uso terapêutico , Miastenia Gravis/tratamento farmacológico , Receptores Colinérgicos/uso terapêutico
18.
Ann Thorac Surg ; 114(5): 1886-1894, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-34736927

RESUMO

BACKGROUND: The Maastricht University Medical Center+ is a Dutch center of expertise appointed by the Netherlands Federation of University Medical Centers for the treatment of thymomas. The aim of this study was to investigate the long-term oncologic, surgical, and neurologic outcomes of all patients who underwent a robotic thymectomy for a thymoma at Maastricht University Medical Center+. METHODS: We retrospectively analyzed the clinical-pathologic data of all consecutive patients with a thymoma who underwent robotic thymectomy using the DaVinci robotic system at Maastricht University Medical Center+ between April 2004 and December 2018. Follow-up data were collected from 60 referring Dutch hospitals. RESULTS: In total, 398 robotic thymectomies were performed, and 130 thymomas (32.7%) were found. Median follow-up time was 46 months; median procedure time, 116 minutes; and median hospitalization time, 3 days. In 8.4% of patients, a conversion was performed, and in 20.8%, a complication was registered. The majority of myasthenic patients with a thymoma went into remission, mostly within 12 to 24 months after thymectomy (81%). No statistical difference was found in the number of complications, conversions, incomplete resections, or deaths between patients with myasthenia gravis and nonmyasthenic patients. Thirty-six patients (27.7%) underwent postoperative radiotherapy. The recurrence rate was 9.1%, and the 5-year thymoma-related survival rate was 96.6%. CONCLUSIONS: Robotic thymectomy was found to be safe and feasible for early stage thymomas, most advanced-stage thymomas, and thymomatous myasthenia gravis. A national guideline could contribute to the improvement of the oncologic follow-up of thymic epithelial tumors in the Netherlands.


Assuntos
Miastenia Gravis , Procedimentos Cirúrgicos Robóticos , Timoma , Neoplasias do Timo , Humanos , Timectomia/métodos , Timoma/patologia , Seguimentos , Estudos Retrospectivos , Procedimentos Cirúrgicos Robóticos/métodos , Países Baixos/epidemiologia , Neoplasias do Timo/cirurgia , Neoplasias do Timo/patologia , Miastenia Gravis/cirurgia , Miastenia Gravis/etiologia , Resultado do Tratamento
19.
J Peripher Nerv Syst ; 16(1): 24-9, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21504499

RESUMO

Myotonic dystrophy 1 (DM1) is characterized by a wide range of clinical features. We aimed to verify the presence of peripheral nerve involvement in a large cohort of DM1 patients and to determine clinical consequences. A total of 93 patients underwent detailed neurological examination and nerve conduction studies. Additionally, balance impairment was assessed with the Berg Balance Scale and health status was evaluated with the SF-36 health survey. Sensory symptoms were not reported and mild sensory signs were found in six patients. Electrophysiological abnormalities consistent with a diagnosis of neuropathy were found in 16 patients (17%). Peripheral nerve involvement was significantly associated with decreased muscle strength (p = 0.001) and absence of Achilles-tendon reflexes (p = 0.003), but not with age or duration of neuromuscular symptoms. It had no significant effect on balance, mental or physical health. In conclusion, peripheral nerve involvement may be one of the multisystemic manifestations of DM1, but is usually subclinical. Other causes should be excluded when sensory symptoms or signs are severe.


Assuntos
Doenças do Sistema Nervoso Periférico/etiologia , Adulto , Eletrofisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Distrofia Miotônica/complicações , Distrofia Miotônica/fisiopatologia , Condução Nervosa/fisiologia , Exame Neurológico , Doenças do Sistema Nervoso Periférico/fisiopatologia
20.
Mol Ther ; 18(6): 1183-91, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20389292

RESUMO

Viral gene transfer or transgenic animals are commonly used technologies to alter gene expression in the adult brain, although these approaches lack spatial specificity and are time consuming. We delivered plasmid DNA locally into the brain of adult C57BL/6 mice in vivo by voltage- and current-controlled electroporation. The low current-controlled delivery of unipolar square wave pulses of 125 µA with microstimulation electrodes at the injection site gave 16 times higher transfection rates than a voltage-controlled electroporation protocol with plate electrodes resulting in currents of about 400 mA. Transfection was restricted to the target region and no damage due to the electric pulses was found. Our current-controlled electroporation protocol indicated that the use of very low currents resulting in applied voltages within the physiological range of the membrane potential, allows efficient transfection of nonviral plasmid DNA. In conclusion, low current-controlled electroporation is an excellent approach for electroporation in the adult brain, i.e., gene function can be influenced locally at a high level with no mortality and minimal tissue damage.


Assuntos
Encéfalo/metabolismo , Eletroporação/métodos , Plasmídeos/administração & dosagem , Transfecção/métodos , Animais , Encéfalo/cirurgia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Plasmídeos/genética , Técnicas Estereotáxicas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA